Updated:
iCarbonX
iCarbonX was founded in 2015 by Wang Jun, the Chinese genomics pioneer who previously co-founded BGI Group, one of the world's largest genomic research...
iCarbonX
iCarbonX was founded in 2015 by Wang Jun, the Chinese genomics pioneer who previously co-founded BGI Group, one of the world's largest genomic research organizations. Wang's departure from BGI allowed him to establish iCarbonX as a vehicle for next-generation digital health investments, anchored around a platform that aggregates genomic, proteomic, and microbiome data to generate personalized health insights. The firm's strategy spans direct investments in AI-driven diagnostics, wearable health monitoring, and multi-omics research platforms. Known portfolio positions include a partnership with the Israeli startup Medial EarlySign, which uses machine learning to detect early disease markers, and a collaborative venture with the Chinese company Focused Photonics to develop non-invasive health sensors. iCarbonX operates across China, Israel, and the United States, with investments in clinical-stage biotech and health-data infrastructure. Wang Jun has publicly stated that iCarbonX raised over $600 million from investors including Tencent Holdings and the China International Capital Corporation, although the firm's total AUM remains undisclosed. The firm maintains a lean operational team in Shenzhen and has not disclosed additional offices or charitable structures. In 2021, iCarbonX sought to expand its digital health platform through a partnership with the Swiss pharmaceutical company Novartis, though details on the collaboration's current status remain sparse. iCarbonX's structural differentiator lies in its dual role as both a family office and an operational platform — the firm builds its own cloud-based AI health system, called the 'Mountain Base', while simultaneously investing externally in complementary startups. This hybrid model, blending corporate venture capital with private wealth management, is rare among Chinese family offices and positions iCarbonX as both a capital allocator and an industry integrator in digital health.
General information
Firm type
Single Family Office
Year founded
2015
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shenzhen
Corporate office
Shenzhen, Guangdong, China
Principals
Wang Jun
Founder and CEO
Sector focus
Frequently asked questions
Who runs investment decisions at iCarbonX?
Wang Jun, the founder and CEO of iCarbonX, makes the primary investment decisions for the firm. Wang previously founded BGI Group, the world's largest genomics research institute, and brings a science-driven approach to capital allocation. The firm does not publicly list a separate CIO or investment committee beyond its founder.
How does iCarbonX source proprietary deal flow?
iCarbonX generates deal flow primarily through Wang Jun's network in the global genomics and digital health ecosystem, built during his tenure at BGI. The firm also leverages its own data platform, iCarbonX Cloud, to identify early-stage companies with complementary technologies. Some investments arise from joint ventures and partnerships, such as its collaboration with Novartis.
Is iCarbonX structured as a single family office or does it operate more like a venture firm?
iCarbonX functions as a single-family office that also operates as a strategic venture builder. The firm makes direct investments via its balance sheet and engages in joint ventures with external partners. In addition, iCarbonX develops proprietary platforms like the 'Mountain Base', which complicates the traditional family office vs. venture firm distinction.
What investment stages does iCarbonX typically target?
iCarbonX tends to invest in growth-stage and venture-stage companies within the digital health and life sciences sectors. The firm has also backed early clinical-stage diagnostics and infrastructure projects. It favors equity stakes that allow for strategic collaboration, often taking board-level involvement.
Which sectors does iCarbonX explicitly avoid?
iCarbonX has no publicly stated list of avoided sectors. However, the firm's disclosed investments and partnerships center exclusively on healthcare, genomics, and digital health. There is no evidence that the firm invests in real estate, energy, or traditional financial assets.
How is iCarbonX related to BGI Group?
iCarbonX was founded by Wang Jun after he left BGI Group, the genomics conglomerate he co-founded. The two entities are independent, though Wang's reputation and network from BGI directly shaped iCarbonX's investment focus on genomics and multi-omics health. iCarbonX does not appear to hold an equity stake in BGI Group.
Where does the underlying wealth come from?
The wealth behind iCarbonX originates from Wang Jun's earlier success as co-founder and former CEO of BGI Group, one of the world's largest genomic research organizations. BGI was valued at over $2 billion in 2015 (per Financial Times, 2015). iCarbonX also raised external capital from Tencent and other investors, but the firm is primarily funded by Wang Jun's personal fortune.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: